Docoh
Loading...

INTI Inhibitor Therapeutics

HedgePath Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which discovers, develops and plans to commercialize therapeutics for patients with cancer. It also explores acquiring or licensing therapeutics addressing unmet needs and orphan indications beyond cancer. The company was founded on September 30, 1992 and is headquartered in Tampa, FL.

Company profile

Ticker
INTI
Exchange
CEO
Nicholas Jon Virca
Employees
Incorporated
Location
Fiscal year end
Former names
COMMONWEALTH BIOTECHNOLOGIES INC, HedgePath Pharmaceuticals, Inc.
SEC CIK
IRS number
541641133

INTI stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

14 May 21
29 Jul 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 84.19K 84.19K 84.19K 84.19K 84.19K 84.19K
Cash burn (monthly) (positive/no burn) 18.21K 55.92K 70.11K 30.62K 34.67K
Cash used (since last report) n/a 72.11K 221.44K 277.64K 121.27K 137.32K
Cash remaining n/a 12.08K -137.25K -193.45K -37.08K -53.13K
Runway (months of cash) n/a 0.7 -2.5 -2.8 -1.2 -1.5

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
15 Jan 21 Mayne Pharma Ventures Pty Common Stock Other Aquire J No No 0 2,240,488 0 204,083,227
22 Dec 20 Garrison J. Hasara Common Stock Option Common Stock Grant Aquire A No No 0.031 125,000 3.88K 125,000
22 Dec 20 Ono Richard Dana Common Stock Option Common Stock Grant Aquire A No No 0.031 754,839 23.4K 754,839
22 Dec 20 Peattie Debra Common Stock Option Common Stock Grant Aquire A No No 0.031 580,646 18K 580,646
22 Dec 20 Martin Robert Daniel Common Stock Option Common Stock Grant Aquire A No No 0.031 754,839 23.4K 754,839

Financial report summary

?
Management Discussion
  • Research and Development Expenses. We recognized less than $0.01 million in research and development expenses during the three months ended March 31, 2021 compared to approximately $0.1 million for the three months ended March 31, 2020. Research and development expenses for the three months ended March 31, 2020 primarily included salary expenses and expenses related to follow-up with the FDA on the Investigational New Drug application for use of SUBA-Itraconazole for prostate cancer that was cleared by the FDA in late 2019. The expenses for the three months ended March 31, 2021 primarily included patent expenses and minimal expenses related to filing the FDA annual report related to the prostate cancer program.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: adjusted, aggregate, amortized, Bank, bankruptcy, bringing, capable, component, coordinating, credit, Dana, Debra, discretion, disinterested, dissolution, drawdown, drawn, entered, entitled, equal, event, exceed, free, gain, independent, insolvent, institution, judgment, Mark, monthly, negative, negotiated, notice, Ono, Peattie, plaintiff, preceding, premium, Prime, principal, purpose, Putative, receipt, Release, remedy, repayment, Reserve, SBA, Statistical, statutory, tied, twenty, validly, waste, Watson
Removed: adversely, applying, authorization, award, castrate, chemotherapy, consulting, cost, Del, dividend, downturn, economy, employee, global, goal, impacted, IND, judgement, life, pricing, provision, reduced, referred, resistant, service, subsequent, testing, weighted